Physician profile
Thomas R Evans
NPI 1033209846
$24,538.72
in general payments reported to CMS, 2019-2025
49 companies · $2,516 in 2025
The $2,516 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,361 · 2020: $3,069 · 2021: $4,140 · 2022: $3,814 · 2023: $1,845 · 2024: $2,794 · 2025: $2,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,154.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,919.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $2,174.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,892.17 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $1,412.51 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,383.26 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,338.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,280.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $1,087.89 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $882.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $870.50 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.62 | 2022-2025 | Caplyta |
| Allergan, INC. | $594.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $534.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $504.66 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $458.27 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.